• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立 UHPLC-MS/MS 法测定新型 FLT3 抑制剂吲达莫司汀衍生物在大鼠体内的药代动力学。

Development of UHPLC-MS/MS Method for Indirubin-3'-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats.

机构信息

College of Pharmacy, Dankook University, Cheonan 31116, Korea.

School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Korea.

出版信息

Molecules. 2020 Apr 27;25(9):2039. doi: 10.3390/molecules25092039.

DOI:10.3390/molecules25092039
PMID:32349415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7248905/
Abstract

This study aimed to develop and validate a sensitive liquid chromatography-coupled tandem mass spectrometry method for the quantification of LDD-2614, an indirubin derivative and novel FLT3 inhibitor, in rat plasma. In addition, the developed analytical method was applied to observe the pharmacokinetic properties of LDD-2614. Chromatographic separation was achieved on a Luna omega C column using a mixture of water and acetonitrile, both containing 0.1% formic acid. Quantitation was performed using positive electrospray ionization in a multiple reaction monitoring (MRM) mode. The MRM transitions were optimized as 426.2→113.1 for LDD-2614 and 390.2→113.1 for LDD-2633 (internal standard), and the lower limit of quantification (LLOQ) for LDD-2614 was determined as 0.1 ng/mL. Including the LLOQ, the nine-point calibration curve was linear with a correlation coefficient greater than 0.9991. Inter- and intraday accuracies (RE) ranged from -3.19% to 8.72%, and the precision was within 9.02%. All validation results (accuracy, precision, matrix effect, recovery, stability, and dilution integrity) met the acceptance criteria of the U.S. Food and Drug Administration and the Korea Ministry of Food and Drug Safety guidelines. The proposed method was validated and demonstrated to be suitable for the quantification of LDD-2614 for pharmacokinetics studies.

摘要

本研究旨在开发和验证一种灵敏的液相色谱-串联质谱法,用于定量测定 LDD-2614,这是一种靛玉红衍生物和新型 FLT3 抑制剂,在大鼠血浆中。此外,所开发的分析方法还用于观察 LDD-2614 的药代动力学特性。色谱分离在 Luna omega C 柱上实现,使用水和乙腈的混合物,两者均含有 0.1%甲酸。定量采用正电喷雾电离在多重反应监测(MRM)模式下进行。MRM 跃迁被优化为 426.2→113.1 用于 LDD-2614 和 390.2→113.1 用于 LDD-2633(内标),LDD-2614 的定量下限(LLOQ)确定为 0.1ng/mL。包括 LLOQ,九点校准曲线呈线性,相关系数大于 0.9991。日内和日间准确度(RE)范围为-3.19%至 8.72%,精密度在 9.02%以内。所有验证结果(准确度、精密度、基质效应、回收率、稳定性和稀释完整性)均符合美国食品和药物管理局和韩国食品药品安全部指南的验收标准。所提出的方法经过验证,适用于 LDD-2614 的药代动力学研究的定量测定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc9/7248905/c24604125c8a/molecules-25-02039-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc9/7248905/99595faf91d7/molecules-25-02039-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc9/7248905/24d0cbe8b944/molecules-25-02039-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc9/7248905/c24604125c8a/molecules-25-02039-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc9/7248905/99595faf91d7/molecules-25-02039-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc9/7248905/24d0cbe8b944/molecules-25-02039-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc9/7248905/c24604125c8a/molecules-25-02039-g003.jpg

相似文献

1
Development of UHPLC-MS/MS Method for Indirubin-3'-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats.建立 UHPLC-MS/MS 法测定新型 FLT3 抑制剂吲达莫司汀衍生物在大鼠体内的药代动力学。
Molecules. 2020 Apr 27;25(9):2039. doi: 10.3390/molecules25092039.
2
Preliminary pharmacokinetic study of the anticancer 6BIO in mice using an UHPLC-MS/MS approach.采用 UHPLC-MS/MS 法研究抗癌 6BIO 在小鼠体内的初步药代动力学。
J Pharm Biomed Anal. 2019 Feb 5;164:317-325. doi: 10.1016/j.jpba.2018.10.039. Epub 2018 Oct 25.
3
Determination of isosinensetin in rat plasma by UHPLC-MS/MS: Application to oral and intravenous pharmacokinetic study in healthy rats.超高效液相色谱-串联质谱法测定大鼠血浆中的异钩藤碱:在健康大鼠口服和静脉给药的药代动力学研究中的应用
J Pharm Biomed Anal. 2020 May 30;184:113210. doi: 10.1016/j.jpba.2020.113210. Epub 2020 Feb 26.
4
Determination of fascaplysin in rat plasma with ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS): application to a pharmacokinetic study.采用超高效液相色谱-串联质谱法(UPLC-MS/MS)测定大鼠血浆中的法沙培林:在药代动力学研究中的应用。
J Pharm Biomed Anal. 2019 Jul 15;171:126-131. doi: 10.1016/j.jpba.2019.04.012. Epub 2019 Apr 8.
5
Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats.建立并验证了一种用于血浆中莫特沙尼检测的 UPLC-MS/MS 方法:在大鼠中的代谢稳定性和药代动力学研究中的应用。
J Pharm Biomed Anal. 2019 Mar 20;166:244-251. doi: 10.1016/j.jpba.2019.01.023. Epub 2019 Jan 14.
6
Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.液相色谱-电喷雾电离串联质谱法测定大鼠血浆中具有抗癌活性的新型三激酶抑制剂JI-101的高灵敏度方法:在药代动力学研究中的应用
Biomed Chromatogr. 2011 Jul;25(7):794-800. doi: 10.1002/bmc.1518. Epub 2010 Sep 27.
7
Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats.大鼠体内7β-(3-乙基-顺式巴豆酰氧基)-1α-(2-甲基丁酰氧基)-3,14-脱氢-Z-去甲莪术二酮药代动力学评价的液相色谱-串联质谱法的建立与验证
Molecules. 2020 Apr 13;25(8):1774. doi: 10.3390/molecules25081774.
8
A rapid UHPLC-MS/MS method for the quantification of ARQ531 in rat plasma: Validation and its application to a pharmacokinetic study.一种快速 UHPLC-MS/MS 法测定大鼠血浆中 ARQ531 的浓度:方法学验证及其在药代动力学研究中的应用。
Biomed Chromatogr. 2020 Nov;34(11):e4937. doi: 10.1002/bmc.4937. Epub 2020 Jul 14.
9
An UPLC-MS/MS method for the quantitation of alectinib in rat plasma.一种用于定量大鼠血浆中阿来替尼的超高效液相色谱-串联质谱法。
J Pharm Biomed Anal. 2017 Jan 5;132:227-231. doi: 10.1016/j.jpba.2016.10.010. Epub 2016 Oct 14.
10
A validated UHPLC-MS/MS method for measurement of pharmacokinetics and tissue distribution of trolline in rat.一种经验证的 UHPLC-MS/MS 方法,用于测量大鼠中延胡索乙素的药代动力学和组织分布。
J Pharm Biomed Anal. 2019 May 30;169:208-214. doi: 10.1016/j.jpba.2019.03.012. Epub 2019 Mar 6.

引用本文的文献

1
A Sensitive LC-MS/MS Method for the Simultaneous Determination of Two Thia-Analogous Indirubin -Glycosides and Indirubin-3'-Monoxime in Plasma and Cell Culture Medium.一种灵敏的 LC-MS/MS 法用于同时测定血浆和细胞培养液中的两种噻吩类似物靛玉红-糖苷和靛玉红-3'-单肟。
Molecules. 2022 May 9;27(9):3031. doi: 10.3390/molecules27093031.

本文引用的文献

1
Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.发现具有口服活性的靛玉红-3'-肟衍生物,作为治疗急性髓系白血病的强效 1 型 FLT3 抑制剂。
Eur J Med Chem. 2020 Jun 1;195:112205. doi: 10.1016/j.ejmech.2020.112205. Epub 2020 Mar 6.
2
inhibitor quizartinib (AC220).抑制剂 quizartinib(AC220)。
Leuk Lymphoma. 2019 Aug;60(8):1866-1876. doi: 10.1080/10428194.2019.1602263. Epub 2019 Apr 18.
3
Discovery of LDD-1075 as a potent FLT3 inhibitor.发现LDD - 1075作为一种有效的FLT3抑制剂。
Oncol Lett. 2019 May;17(5):4735-4741. doi: 10.3892/ol.2019.10096. Epub 2019 Mar 1.
4
Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.推进急性髓细胞白血病治疗:FLT3 抑制剂的未来。
Expert Rev Anticancer Ther. 2019 Mar;19(3):273-286. doi: 10.1080/14737140.2019.1573679. Epub 2019 Feb 6.
5
FLT3 inhibitors in acute myeloid leukemia.FLT3 抑制剂在急性髓系白血病中的应用。
J Hematol Oncol. 2018 Dec 4;11(1):133. doi: 10.1186/s13045-018-0675-4.
6
Clinical use of FLT3 inhibitors in acute myeloid leukemia.FLT3抑制剂在急性髓系白血病中的临床应用。
Onco Targets Ther. 2018 Oct 16;11:7041-7052. doi: 10.2147/OTT.S171640. eCollection 2018.
7
FLT3 inhibitors in acute myeloid leukemia: Current and future.急性髓系白血病中的FLT3抑制剂:现状与未来。
J Oncol Pharm Pract. 2019 Jan;25(1):163-171. doi: 10.1177/1078155218802620. Epub 2018 Sep 30.
8
Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis.FLT3抑制剂在急性髓系白血病缓解诱导或挽救治疗中的应用:系统评价与荟萃分析
Cancer Manag Res. 2018 Aug 14;10:2635-2652. doi: 10.2147/CMAR.S166387. eCollection 2018.
9
Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.更正:发现FLT3抑制剂LDD1937作为急性髓性白血病的抗白血病药物。
Oncotarget. 2018 Apr 13;9(28):20219. doi: 10.18632/oncotarget.25141.
10
Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.靶向FLT3的酪氨酸激酶抑制剂在急性髓系白血病治疗中的应用
Stem Cell Investig. 2017 Jun 2;4:48. doi: 10.21037/sci.2017.05.04. eCollection 2017.